1. Immunotherapy for Advanced Melanoma
Lei Fang, Anke S. Lonsdorf, Sam T. Hwang 
Journal of Investigative Dermatology 
Volume 128, Issue 11, Pages (November 2008)
DOI: /jid
Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

2. Figure 1
Strategy for immunotherapy of melanoma. CTL, cytotoxic T lymphocyte; DLN, draining lymph node; PBMC, peripheral blood mononuclear cells; CTLA, cytotoxic T lymphocyte antigen; TIL, tumor-infiltrating lymphocyte; HSC, hematopoietic stem cell.
Journal of Investigative Dermatology  , DOI: ( /jid )
Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

3. Figure 2
Skin dermatitis following treatment with anti-CTLA-4 mAb as a single agent as described in Jaber et al. (2006). (a) Photodistributed macules and papules on face and neck, and (b) erythematous papules with Koebner-like phenomenon elicited by the trauma of scratching.
Journal of Investigative Dermatology  , DOI: ( /jid )
Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

4. Figure 3
Response of a melanoma tumor to a lymphodepleting chemotherapy regimen combined with adoptive transfer of tumor-infiltrating T cells (Dudley et al., 2002a).
(photo courtesy of Dr Steven A. Rosenberg, Surgery Branch, NCI).
Journal of Investigative Dermatology  , DOI: ( /jid )
Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions